

# Macular translocation with 360° retinotomy for wet age-related macular degeneration

Interventional procedures guidance

Published: 19 May 2010

[nice.org.uk/guidance/ipg340](https://www.nice.org.uk/guidance/ipg340)

## Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

This guidance replaces IPG48.

## 1 Guidance

- 1.1 Current evidence on macular translocation with 360° retinotomy for wet age-related macular degeneration (AMD) shows that this procedure is efficacious in only a proportion of patients and that there is a potential for serious adverse events. Therefore the procedure should only be used with special arrangements for clinical governance, consent and audit or research.
- 1.2 Clinicians wishing to undertake macular translocation with 360° retinotomy for wet AMD should take the following actions.
- Inform the clinical governance leads in their Trusts.
  - Ensure that patients and their carers understand the uncertainty about the procedure's safety and efficacy and provide them with clear information about both this procedure and alternative treatments (see section 2.5.1). In addition, the use of NICE's [information for patients](#) ('Understanding NICE guidance') is recommended.
  - Audit and review clinical outcomes of all patients having macular translocation with 360° retinotomy for wet AMD (see section 3.1).

## 2 The procedure

### 2.1 *Indications and current treatments*

- 2.1.1 AMD is the most common cause of blindness in developed countries. A small proportion of patients with AMD have wet AMD. Wet AMD is characterised by the abnormal growth of blood vessels in the choroid layer underneath the macular part of the retina. These vessels can threaten vision if they leak and cause scarring.
- 2.1.2 Current treatments for wet AMD include laser photocoagulation, photodynamic therapy (PDT), intravitreal injections of antivascular endothelial growth factor agents and implantation of miniature lens systems. Patients with advanced disease may benefit from optical aids such as magnifying glasses.

## 2.2 *Outline of the procedure*

- 2.2.1 The aim of this procedure is to move the macula so that it lies over a healthier part of the choroid layer that is unaffected by neovascularisation.
- 2.2.2 In macular translocation with 360° retinotomy for wet AMD, a vitrectomy is done and the retina is then detached from the back of the eye using an injection of saline solution. An incision is made around the entire perimeter of the retina so that it is freely mobile, and attached only at the optic disc. The abnormal choroidal vessels are removed and the retina is reattached with the macula rotated away from the original disease site. Once the retina is reattached the vitreous cavity is injected with silicone oil for tamponade. In a second operation approximately 1–2 months later, the whole globe is rotated in the opposite direction by dividing and reattaching the external ocular muscles in order to remove the resulting visual disturbance caused by the torsion, and the silicone oil is drained from the vitreous cavity.

Sections 2.3 and 2.4 describe efficacy and safety outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the [overview](#).

## 2.3 *Efficacy*

- 2.3.1 A randomised controlled trial (RCT) of 50 patients treated by the procedure or PDT reported an increase of 3 lines or more of best corrected visual acuity (BCVA) in 28% (7/25) and 0% (0/25) of patients respectively at 24-month follow-up ( $p < 0.01$ ). A case series of 50 patients reported 2-line or greater BCVA improvement in 66% (33/50), no improvement in 28% (14/50) and a loss of more than 2 lines in 6% (3/50) of patients at 21-month follow-up. A case series of 64 patients reported BCVA improvement of 1 line or more in 52% (32/61) and a loss of more than 3 lines in 11% (7/61) of patients at 12-month follow-up.
- 2.3.2 A non-randomised controlled study of 24 patients reported that mean BCVA improved from 0.90 to 0.69 logMAR in 12 patients treated by the procedure ( $p = 0.09$ ) and worsened from 0.87 to 1.38 logMAR in 12 patients treated by choroidal patch graft at 3-year follow-up ( $p < 0.001$ ).

- 2.3.3 The case series of 64 patients reported that median reading speed improved among 55 patients from 71 words per minute at baseline to 105 words per minute at 12-month follow-up ( $p < 0.001$ ).
- 2.3.4 The RCT of 50 patients reported no difference in quality-of-life scores between patients treated by the procedure or PDT for general vision ( $p = 0.27$ ) at 24-month follow-up.
- 2.3.5 The Specialist Advisers listed key efficacy outcomes as attached retina following surgery, functional outcomes of BCVA, and reading speed.

## 2.4 *Safety*

- 2.4.1 Retinal detachment (requiring vitrectomy and endotamponade for reattachment) was reported in 24% (6/25) of patients treated by the procedure in the RCT of 50 patients. In case series of 90 and 64 patients, retinal detachment was reported in 19% (absolute figures not stated) and 8% (5/61) of patients respectively (12-month follow-up for both studies).
- 2.4.2 In the non-randomised controlled study of 24 patients, residual torsion requiring a third procedure was reported in 17% (2/12) of patients treated by the procedure (timing of events not stated).
- 2.4.3 Retinal slippage from the desired final location after translocation was reported in 3% (2/75) of eyes in the case series of 75 eyes (number of patients not stated).
- 2.4.4 The Specialist Advisers stated that adverse events reported in the literature include proliferative vitreoretinopathy, macular oedema, diplopia and phthisis. They listed theoretical adverse events as recurrence of neovascularisation.

## 2.5 *Other comments*

- 2.5.1 The Committee noted that intravitreal injections of antivascular endothelial growth factor agents are more commonly used for the treatment of AMD than surgical techniques. For more information see '[Ranibizumab and pegaptanib for the treatment of age-related macular degeneration](#)' (NICE technology appraisal guidance 155).

### 3 Further information

- 3.1 This guidance requires that clinicians undertaking the procedure make special arrangements for audit. NICE has identified relevant audit criteria and developed [audit support](#) (which is for use at local discretion).
- 3.2 For related NICE guidance see our [website](#).

#### *Information for patients*

NICE has produced [information on this procedure for patients and carers](#) ('Understanding NICE guidance'). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.

### 4 Other NICE recommendations on macular translocation

NICE has also issued full guidance on [Limited macular translocation for wet age related macular degeneration](#) (Interventional Procedures Guidance no. 339)

These replace the previous guidance on Macular translocation for age-related macular degeneration (Interventional Procedures Guidance no. 48, March 2004).

If you wish to be updated to any developments with this procedure, you can express an interest via our [website](#).

### 5 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE [interventional procedure guidance](#) process.

We have produced a [summary of this guidance for patients and carers](#). Tools to help you put the guidance into practice and information about the evidence it is based on are also [available](#).

## Changes since publication

4 January 2012: minor maintenance.

## Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

## Copyright

© National Institute for Health and Clinical Excellence 2010. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

## Contact NICE

National Institute for Health and Clinical Excellence  
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

[www.nice.org.uk](http://www.nice.org.uk)

[nice@nice.org.uk](mailto:nice@nice.org.uk)

0845 033 7780

## *Endorsing organisation*

This guidance has been endorsed by [Healthcare Improvement Scotland](#).

## Accreditation

